144 related articles for article (PubMed ID: 36446806)
1. Tools for communicating risk for Parkinson's disease.
Cook L; Schulze J; Uhlmann WR; Verbrugge J; Marder K; Lee AJ; Wang Y; Alcalay RN; Nance M; Beck JC
NPJ Parkinsons Dis; 2022 Nov; 8(1):164. PubMed ID: 36446806
[TBL] [Abstract][Full Text] [Related]
2. Acceptance of technology-based tools in a sample of Parkinson's patients.
Duroseau N; Abramson T; Pergament K; Chan V; Govindavari JP; Ciraco C; Tegay D; Krishnamachari B
Chronic Illn; 2017 Mar; 13(1):3-13. PubMed ID: 27269275
[TBL] [Abstract][Full Text] [Related]
3. Measuring the impact of Parkinson's disease: an occupational therapy perspective.
Gaudet P
Can J Occup Ther; 2002 Apr; 69(2):104-13. PubMed ID: 11977869
[TBL] [Abstract][Full Text] [Related]
4. Communication strategies used by Parkinson's nurse specialists during healthcare interactions: A qualitative descriptive study.
Pitts E; Wylie K; Loftus AM; Cocks N
J Adv Nurs; 2022 Jun; 78(6):1773-1786. PubMed ID: 35285973
[TBL] [Abstract][Full Text] [Related]
5. The initial diagnosis and management of Parkinson's disease.
Waller S; Williams L; Morales-Briceño H; Fung VS
Aust J Gen Pract; 2021 Nov; 50(11):793-800. PubMed ID: 34713282
[TBL] [Abstract][Full Text] [Related]
6. Detecting cognitive impairment in patients with Parkinson's disease with a brief cognitive screening tool: the Addenbrooke's Cognitive Examination (ACE).
Chade A; Roca M; Torralva T; Gleichgerrcht E; Fabbro N; Arévalo GG; Gershanik O; Manes F
Dement Neuropsychol; 2008; 2(3):197-200. PubMed ID: 29213570
[TBL] [Abstract][Full Text] [Related]
7. Excessive daytime sleepiness in patients with Parkinson's disease.
Knie B; Mitra MT; Logishetty K; Chaudhuri KR
CNS Drugs; 2011 Mar; 25(3):203-12. PubMed ID: 21323392
[TBL] [Abstract][Full Text] [Related]
8. Merging Clinical and Imaging Biomarkers to Tackle Parkinson's Disease.
Picillo M; Barone P; Pellecchia MT
Mov Disord Clin Pract; 2017; 4(5):652-662. PubMed ID: 30363377
[TBL] [Abstract][Full Text] [Related]
9. Barriers and facilitators of communication about off periods in Parkinson's disease: Qualitative analysis of patient, carepartner, and physician Interviews.
Armstrong MJ; Rastgardani T; Gagliardi AR; Marras C
PLoS One; 2019; 14(4):e0215384. PubMed ID: 30998707
[TBL] [Abstract][Full Text] [Related]
10. Affective disorders in Parkinson's disease.
Aminian KS; Strafella AP
Curr Opin Neurol; 2013 Aug; 26(4):339-44. PubMed ID: 23757262
[TBL] [Abstract][Full Text] [Related]
11. Validity and Reliability of the Persian Version of Parkinson's Disease Sleep Scale-2.
Joghataei MT; Fereshtehnejad SM; Mehdizadeh M; Goudarzi S; Habibi SAH; Meimandi M; Dehmiyani A; Taghizadeh G
Parkinsons Dis; 2021; 2021():2015123. PubMed ID: 34966538
[TBL] [Abstract][Full Text] [Related]
12. Incidence and risk factors of Parkinson's disease in The Netherlands.
Hofman A; Collette HJ; Bartelds AI
Neuroepidemiology; 1989; 8(6):296-9. PubMed ID: 2586699
[TBL] [Abstract][Full Text] [Related]
13. Integration of palliative care in Parkinson's disease management.
Senderovich H; Jimenez Lopez B
Curr Med Res Opin; 2021 Oct; 37(10):1745-1759. PubMed ID: 34254548
[TBL] [Abstract][Full Text] [Related]
14. The Gastrointestinal Dysfunction Scale for Parkinson's Disease.
Camacho M; Greenland JC; Williams-Gray CH
Mov Disord; 2021 Oct; 36(10):2358-2366. PubMed ID: 34133059
[TBL] [Abstract][Full Text] [Related]
15. Protein network exploration prioritizes targets for modulating neuroinflammation in Parkinson's disease.
Bonte MA; El Idrissi F; Gressier B; Devos D; Belarbi K
Int Immunopharmacol; 2021 Jun; 95():107526. PubMed ID: 33756233
[TBL] [Abstract][Full Text] [Related]
16. Parkinson's Disease-Induced Zebrafish Models: Focussing on Oxidative Stress Implications and Sleep Processes.
Robea MA; Balmus IM; Ciobica A; Strungaru S; Plavan G; Gorgan LD; Savuca A; Nicoara M
Oxid Med Cell Longev; 2020; 2020():1370837. PubMed ID: 32908622
[TBL] [Abstract][Full Text] [Related]
17. Validating the Predicted Effect of Astemizole and Ketoconazole Using a Drosophila Model of Parkinson's Disease.
Styczyńska-Soczka K; Zechini L; Zografos L
Assay Drug Dev Technol; 2017 Apr; 15(3):106-112. PubMed ID: 28418693
[TBL] [Abstract][Full Text] [Related]
18. Network Analysis Identifies Disease-Specific Pathways for Parkinson's Disease.
Monti C; Colugnat I; Lopiano L; Chiò A; Alberio T
Mol Neurobiol; 2018 Jan; 55(1):370-381. PubMed ID: 28004338
[TBL] [Abstract][Full Text] [Related]
19. Accuracy of MR markers for differentiating Progressive Supranuclear Palsy from Parkinson's disease.
Zanigni S; Calandra-Buonaura G; Manners DN; Testa C; Gibertoni D; Evangelisti S; Sambati L; Guarino M; De Massis P; Gramegna LL; Bianchini C; Rucci P; Cortelli P; Lodi R; Tonon C
Neuroimage Clin; 2016; 11():736-742. PubMed ID: 27330973
[TBL] [Abstract][Full Text] [Related]
20. Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons.
Dragicevic E; Poetschke C; Duda J; Schlaudraff F; Lammel S; Schiemann J; Fauler M; Hetzel A; Watanabe M; Lujan R; Malenka RC; Striessnig J; Liss B
Brain; 2014 Aug; 137(Pt 8):2287-302. PubMed ID: 24934288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
